A Reversal for Syndax Pharmaceuticals, Inc. (SNDX) Is Not Near. The Stock Rises Again

April 17, 2018 - By Peter Erickson

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Logo

The stock of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) is a huge mover today! The stock increased 6.78% or $0.73 during the last trading session, reaching $11.49. About 280,029 shares traded. Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) has risen 7.53% since April 17, 2017 and is uptrending. It has underperformed by 4.02% the S&P500.
The move comes after 9 months positive chart setup for the $283.78M company. It was reported on Apr, 17 by Barchart.com. We have $12.41 PT which if reached, will make NASDAQ:SNDX worth $22.70M more.

Analysts await Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) to report earnings on May, 14. They expect $-0.94 earnings per share, down 32.39 % or $0.23 from last year’s $-0.71 per share. After $-0.80 actual earnings per share reported by Syndax Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 17.50 % negative EPS growth.

Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapies for various cancer indications. The company has market cap of $283.78 million. The companyÂ’s lead product candidate is Entinostat, which is in Phase III clinical trial for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative, and breast cancer; and Phase 2b clinical trial. It currently has negative earnings. It also develops SNDX-6352, an immunoglobulin G subclass 4 isotype that binds to the ligand binding domain of CSF-1R, blocking the binding and consequent activation by natural ligands interleukin-34 and colony stimulating factor-1, and disrupting tumor-associated macrophages activity.

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: